New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCagrilintide vs MOTS-c

Cagrilintide vs MOTS-c

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Cagrilintide
Anti-Aging & Longevity
MOTS-c
Summary
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Half-Life
~7–10 days
Estimated 1–2 hours
Admin Route
SubQ
SubQ
Research
Typical Dose
0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
5–15 mg
Frequency
Once weekly
3–5 times per week
Key Benefits
  • ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
  • Synergistic appetite suppression complementing GLP-1 receptor agonists
  • Reduces post-meal glucagon excursions improving glycemic control
  • Slows gastric emptying contributing to prolonged satiety
  • Once-weekly dosing via subcutaneous injection
  • Potential for greater weight loss than semaglutide monotherapy
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
Side Effects
  • Nausea (most common, especially during titration)
  • Vomiting
  • Decreased appetite
  • Diarrhea
  • +2 more
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
Stacks With